Amryt Pharma

What Amryt Pharma does

Amryt Pharma was a global commercial-stage biopharmaceutical company focused on acquiring, developing, and commercializing treatments for rare and orphan diseases. Founded in 2012 and headquartered in Dublin, Ireland (with a registered office in London and US operations in Boston), the company built a portfolio of four approved products targeting ultra-rare conditions: metreleptin (Myalept®/Myalepta®) for lipodystrophy, oral octreotide (Mycapssa®) for acromegaly, lomitapide (Juxtapid®/Lojuxta®) for Homozygous Familial Hypercholesterolaemia (HoFH), and Oleogel-S10 (Filsuvez®) for Epidermolysis Bullosa (EB). Patients with these conditions typically had limited or no prior treatment options, and Amryt's portfolio addressed HoFH, generalized and partial lipodystrophy, junctional and dystrophic EB, and acromegaly maintenance therapy across the US, EU, Canada, Brazil, Argentina, Colombia, Japan, Israel, and Saudi Arabia.

The company's technology backbone centered on the proprietary Transient Permeability Enhancer (TPE®) platform—an enteric-coated oral delivery technology that protects peptide-based drugs from gastric degradation and induces transient expansion of intestinal tight junctions to enable systemic absorption of macromolecules. TPE® underpinned Mycapssa®, the first and only FDA- and EC-approved oral somatostatin analog. A second platform—a polymer-based gene therapy delivery system—supported the pre-clinical candidate AP103 for Dystrophic EB, with potential applicability across other genetic disorders. Amryt's commercial portfolio was assembled largely through M&A, notably the 2019 acquisition of Aegerion Pharmaceuticals (USD $190.7 million) and the 2021 all-stock acquisition of Chiasma, Inc., and was reinforced by orphan-drug regulatory exclusivities in both the US and EU.

Amryt operated a sales-led go-to-market model combining direct field-sales teams engaging specialist physicians (endocrinologists, lipidologists, dermatologists) with regional distribution partnerships (e.g., SWIXX) and specialty pharmacy/hospital channels. Revenue was generated through prescription drug sales reimbursed by insurance and government healthcare programs, with pricing not publicly disclosed. The company supplemented commercial revenue with non-dilutive financing (a USD $125 million Ares Management debt refinancing in February 2022) and capital-markets activity (Nasdaq listing in July 2020, AIM delisting in January 2022). In 2023, Amryt was acquired by Italian pharmaceutical company Chiesi Farmaceutici S.p.A. for €1.3 billion, the largest M&A transaction in Ireland that year, ending its status as an independent public company.

Name

Amryt Pharma

Legal name

Amryt Pharma plc

Website

http://www.amrytpharma.com

Company type

Public

Founded year

2012

Operating status

Acquired

Headcount range

251–500 employees

Short description

Amryt Pharma was a Dublin-based, commercial-stage biopharmaceutical company developing and commercializing treatments for rare and orphan diseases, including lipodystrophy, acromegaly, HoFH, and Epidermolysis Bullosa, via four approved products and the proprietary TPE® oral peptide delivery platform; acquired by Chiesi Farmaceutici in 2023.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Orphan disease therapeutics
• Rare disease medicines
• Oral peptide delivery
• Specialty biopharmaceuticals
• Gene therapy pipeline

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Amryt generates revenue through the sale of commercial pharmaceutical products for rare diseases. The company has four approved commercial products: metreleptin (Myalept®/Myalepta®), oral octreotide (Mycapssa®), lomitapide (Juxtapid®/Lojuxta®), and Oleogel-S10 (Filsuvez®). Revenue is derived from prescription drug sales to patients with rare conditions, typically covered by insurance or government healthcare programs.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Amryt Pharma is a global commercial-stage biopharmaceutical company that acquires, develops, and commercializes innovative treatments for rare and orphan diseases. Its commercial portfolio comprises four approved products: metreleptin (Myalept®/Myalepta®) for leptin deficiency in lipodystrophy, oral octreotide (Mycapssa®) for acromegaly, lomitapide (Juxtapid®/Lojuxta®) for homozygous familial hypercholesterolaemia, and Oleogel-S10 (Filsuvez®) for epidermolysis bullosa. The portfolio is complemented by a pre-clinical gene therapy candidate AP103 and the proprietary TPE® oral peptide drug delivery platform.

Product overview

Amryt Pharma is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising innovative treatments for rare and orphan diseases. The company's commercial business comprises four orphan disease products: metreleptin (Myalept®/Myalepta®▼) for lipodystrophy; oral octreotide (Mycapssa®) for acromegaly; lomitapide (Juxtapid®/Lojuxta®▼) for homozygous familial hypercholesterolaemia; and Oleogel-S10 (Filsuvez®▼) for epidermolysis bullosa. The portfolio is complemented by a pre-clinical gene therapy candidate AP103 for Dystrophic EB and the proprietary Transient Permeability Enhancer (TPE®) technology platform that enables oral delivery of peptide-based therapies.

Differentiator

Problem solved

Functional benefit

Brands

• Juxtapid/Lojuxta: Brand name for lomitapide, used for treatment of homozygous familial hypercholesterolaemia (HoFH)
• Myalept/Myalepta
• Mycapssa
• Filsuvez
• Oleogel-S10

Products and services

• Myalept® / Myalepta® (metreleptin) Leptin replacement therapy for complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and partial lipodystrophy (PL). Approved as Myalept® in the US and Myalepta® in the EU.
• Mycapssa® (octreotide capsules) First and only oral somatostatin analog approved by FDA and EC for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Developed using proprietary TPE® technology.
• Juxtapid® / Lojuxta® (lomitapide) Oral, selective inhibitor of microsomal triglyceride transfer protein (MTP) approved as adjunct to a low-fat diet for treatment of adults with homozygous familial hypercholesterolaemia (HoFH). Marketed as Juxtapid® in the US, Canada, Colombia, Argentina, and Japan, and as Lojuxta® in the EU, Israel, Saudi Arabia, and Brazil.
• Filsuvez® (Oleogel-S10) Birch triterpenes gel formulation approved in the EU and Great Britain for treatment of partial thickness wounds associated with junctional and dystrophic Epidermolysis Bullosa (EB) in patients 6 months and older.
• AP103 (pre-clinical gene therapy candidate) Pre-clinical gene therapy candidate offering potential treatment for patients with Dystrophic Epidermolysis Bullosa (DEB). The polymer-based delivery platform has potential for development in other genetic disorders.

Quantifiable outcome

• Mycapssa® is the first and only oral somatostatin analog approved by FDA and EC
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and major.

• Chiasma, Inc.coreStrategic or Co-development Partner · 5 May 2021Amryt Pharma announced acquisition of Chiasma, Inc. through an all-stock transaction. The merger created a global leader in rare and orphan diseases with three approved commercial products and a promising pipeline. The combined entity planned to accelerate the launch of MYCAPSSA® and expand market presence globally.
• SWIXXmajorChannel Partner/ Reseller/ Distributor · 3 June 2020Amryt signed a distribution agreement with SWIXX for Myalepta, enabling broader distribution of the lipodystrophy treatment product in specified territories.
• Aegerion PharmaceuticalscoreStrategic or Co-development Partner · 25 September 2019Amryt acquired Aegerion Pharmaceuticals for USD $190.7 million. This acquisition expanded Amryt's commercial portfolio to include Juxtapid®/Lojuxta® (lomitapide) for HoFH treatment. As part of the acquisition, Amryt issued Contingent Value Rights (CVRs) with potential payments of up to US$85 million upon achievement of certain approval and revenue milestones for Oleogel-S10.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Swedish Orphan Biovitrum (Sobi): Sobi is a specialty biopharmaceutical company focused on rare diseases, with a comparable model of acquiring, developing, and commercializing orphan therapies across multiple therapeutic areas, often with a European commercial footprint similar to Amryt.
• BioMarin Pharmaceutical: BioMarin is a leading rare disease biopharmaceutical company developing and commercializing therapies for ultra-rare conditions, comparable to Amryt in its specialty focus, orphan drug strategy, and global commercialization of high-cost rare disease therapies.
• Ultragenyx Pharmaceutical: Ultragenyx is a clinical- and commercial-stage rare disease biopharmaceutical company developing treatments for rare and ultra-rare genetic disorders, comparable to Amryt in its orphan drug focus and pursuit of novel modalities including gene therapy.
• Alexion Pharmaceuticals (AstraZeneca Rare Disease): Alexion, acquired by AstraZeneca, is a global leader in rare disease therapeutics with a focus on complement-mediated and metabolic rare conditions, sharing Amryt's model of orphan drug commercialization, premium pricing, and global distribution infrastructure.
• Recordati Rare Diseases: Recordati Rare Diseases is a specialty division of Recordati focused on rare and orphan disease therapeutics across multiple therapeutic areas, closely comparable to Amryt's positioning as a global commercial-stage rare disease company with an established product portfolio.
• Horizon Therapeutics (Amgen): Horizon Therapeutics, acquired by Amgen in 2023, was a rare and specialty disease-focused biopharma, comparable to Amryt in building a multi-product rare disease franchise through both internal development and bolt-on acquisitions of approved orphan therapies.
• Krystal Biotech: Krystal Biotech developed Vyjuvek, the first FDA-approved gene therapy for Dystrophic Epidermolysis Bullosa, directly comparable to Amryt's Filsuvez franchise and AP103 pre-clinical gene therapy program in the same EB indication.

Others

• Chiesi Farmaceutici S.p.A. Chiesi Farmaceutici is the parent company of Amryt Pharma following the 2023 €1.3B acquisition; included as a peer because Chiesi operates in adjacent rare disease and specialty therapeutic areas and now controls Amryt's commercial strategy and capital allocation.

Broad incumbents

• Takeda Pharmaceutical (Shire Rare Diseases): Takeda's rare disease franchise, built through the Shire acquisition, operates a global specialty rare disease model analogous to Amryt's, with multiple orphan products commercialized worldwide.
• Ipsen: Ipsen is a global specialty biopharmaceutical company with a rare disease and oncology focus, and is a direct competitor in acromegaly through Somatuline Depot (lanreotide), competing with Amryt's Mycapssa in the same indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/amrytpharma
• Facebookfacebook.com/Amryt-Pharma-108296094672123
• LinkedInlinkedin.com/company/amryt-pharma
• Instagraminstagram.com/amrytpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amryt Pharma